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Objectives: Three decades after HIV recognition and its association with AIDS development,
many advances have emerged – especially related to prevention and treatment. Undoubt-
edly, the development of Highly Active Antiretroviral Therapy (HAART) dramatically changed
the  future of the syndrome that we know today. In the present study, we evaluate the impact
of  Highly Active Antiretroviral Therapy on macrophage function and its relevance to HIV
pathogenesis.
Methods: PBMCs were isolated from blood samples and monocytes (CD14+ cells) were puri-
ﬁed.  Monocyte-Derived Macrophages (MDMs) were activated on classical (MGM-CSF+IFN-) or
alternative (MIL-4+IL13) patterns using human recombinant cytokines for six days. After this
period, Monocyte-Derived Macrophages were stimulated with TLR2/Dectin-1 or TLR4 ago-
nists  and we evaluated the inﬂuence of HIV-1 infection and Highly Active Antiretroviral
Therapy on the release of cytokines/chemokines by macrophages.
Results: The data were obtained using Monocyte-Derived Macrophages derived from HIV
naïve or from patients on regular Highly Active Antiretroviral Therapy. Classically Monocyte-
Derived Macrophages obtained from HIV-1 infected patients on Highly Active Antiretroviral
Therapy released higher levels of IL-6 and IL-12 even without PAMPs stimuli when compared
to  control group. On the other hand, alternative Monocyte-Derived Macrophages derived
from  HIV-1 infected patients on Highly Active Antiretroviral Therapy released lower lev-Please cite this article in press as: Galvão-Lima LJ, et al. Classical and alternative macrophages have impaired function during acute and chronic
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.10.004
els  of IL-6, IL-10, TNF-, IP-10 and RANTES after LPS stimuli when compared to control
group. Furthermore, healthy individuals have a complex network of cytokines/chemokines
released by Monocyte-Derived Macrophages after PAMP stimuli, which was deeply affected
in  MDMs obtained from naïve HIV-1 infected patients and only partially restored in MDMs
derived from HIV-1 infected patients even on regular Highly Active Antiretroviral Therapy.
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Conclusion: Our therapy protocols were not effective in restoring the functional alterations
induced by HIV, especially those found on macrophages. These ﬁndings indicate that we still
need to develop new approaches and improve the current therapy protocols, focusing on the
reestablishment of cellular functions and prevention/treatment of opportunistic infections.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
10 ng/mL of LPS (Sigma–Aldrich) or 100 g/mL of -glucanIntroduction
Since the discovery that HIV was the cause of the AIDS and
the establishment of this condition as the main cause of
death associated with infectious diseases, recent data esti-
mate that over 35 million people around the world are living
with HIV.1 During the last three decades, there have been
many advances in the understanding of viral cycle replica-
tion and pathogenesis-related mechanisms. As a result several
antiretroviral drugs were developed. Speciﬁcally, the com-
bined Highly Active Antiretroviral Therapy (HAART) resulted
in the reduction of deaths related to AIDS, helped con-
trolling the viral spread and increased the quality of life
and the life expectancy of HIV-1 infected patients.2–4 How-
ever, many  challenges still hamper the development of new
and more  effective therapeutic approaches to functional
cure.
Classically, the immune dysfunction observed during HIV
infection is directly associated with an intense reduction of
CD4+ T cells in peripheral blood and other tissues includ-
ing intestinal mucosa. In recent years several studies have
demonstrated the contribution of innate immunity to viral
pathogenesis and AIDS development.5–7 This paper will focus
on the role of macrophages, but other authors have explored
the relevance of dendritic cells and neutrophils on HIV
pathogenesis.8–10
Monocyte-Derived Macrophages (MDMs) play a central
role in the immune response, orchestrating the develop-
ment of innate and adaptive immunity to pathogens, and
further, these MDMs  can be infected chronically by HIV.11
Besides remaining viable, HIV infected MDMs can be differ-
ently activated and develop several functional impairments,
with reduced phagocytic and intracellular killing activity, thus
allowing for the occurrence of opportunistic infections.12–14
In the recent years, Chihara and colleagues have demon-
strated that HIV-1 proteins including gp120, Tat, and
Nef induce macrophage polarization towards the classi-
cal pathway13 and, according to Cassol and colleagues,
enable macrophage support for increased viral replication.15
Currently, few papers have evaluated the role of antiretro-
viral drugs on functional immune recovery after the onset
of regular therapy protocols. In our study we evaluated
the inﬂuence of HIV-1 infection on cytokine/chemokine
release by classically (MGM-CSF+IFN-) or alternatively (MIL-4+IL13)Please cite this article in press as: Galvão-Lima LJ, et al. Classical and altern
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
activated MDMs  after PAMPs stimuli on MDMs derived
from treatment-naïve patients or from those on regular
HAART.Material  and  methods
Casuistic  and  selection  criteria
Eight treatment-naïve HIV-1 infected patients on early stage
of disease were recruited for this study. In addition, 15 HIV-
1 infected patients on regular HAART (HIV-1 + HAART) for at
least six months and 15 healthy blood donors were included
as controls (Table 1). Informed consent was obtained from all
participants included in the study. All procedures performed
in the study involving human participants were in accordance
with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
The present study was approved by the Clinical Hospital of
FMRP/USP Ethics Committee (#9817/2012).
Isolation  PBMCs,  puriﬁcation  of  CD14+  cells,  and  MDMs
activation
Peripheral blood mononuclear cells (PBMCs) were isolated
using Ficoll-PaqueTM PLUS (GE Healthcare), following the
manufacturer’s instructions. The obtained PBMCs were quan-
tiﬁed and the monocytes (CD14+ cells) were puriﬁed using
positive selection with magnetic system microbeads (Mil-
tenyi Biotec). After elution, the CD14+ cells were cultured in
48-well plates with RPMI 1640 medium containing 1 L/mL
gentamicin, supplemented with 10% of FBS (Gibco Labora-
tories) and incubated at 37 ◦C, 5% CO2. To induce classical
(MGM-CSF+IFN-) or alternative (MIL-4+IL13) MDMs  activation,
CD14+ cells were cultured for six days in medium contain-
ing GM-CSF (20 ng/mL; R&D Systems) and IFN- (10 ng/mL;
Millipore) or IL-4 and IL-13 (50 ng/mL each; R&D Systems),
respectively. Resting MDMs (M0) were cultured with standard
medium without supplementation of cytokines. Every two
days in culture, fresh medium containing the respective con-
ditions (M0, MGM-CSF+IFN- or MIL-4+IL13) was added to keep cell
viability.
Quantiﬁcation  of  cytokines  and  chemokines  on
supernatant  after  PAMPs  stimuli
After the respective activation, MDMs were stimulated withative macrophages have impaired function during acute and chronic
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extracted from Saccharomyces cerevisiae (Calbiochem, Merck
Millipore) during 24 h. After this period, the supernatant was
collected and nine cytokines and chemokines released (IL-1,
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Table 1 – General characteristics of patients included in the study.
Groups evaluated Control (n = 15) HIV-1+ (n = 8) HIV-1+ under
HAART (n = 15)
Characteristics
Age (years) 28.4 35.7 46.5
Infection time/diagnosis (months) – 20.8 108.7
Time elapsed between diagnosis and start of regular HAART (in months) – – 22.5
Time under regular HAART (months) – – 59.7
CD4+ T cell nadir (cells/mm3) – 382.5 155
CD8+ T cell nadir (cells/mm3) – 1011.1 483.1
CD4+/CD8+ T cell ratio on diagnosis – 0.37 0.32
CD4+ T cell count after regular HAART (cells/mm3) – – 535.4
CD8+ T cell count after regular HAART (cells/mm3) – – 926.6
CD4+/CD8+ T cell ratio after regular HAART – – 0.57
Serum viral load (copies/mL) – 41,868.25 <50a
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(HAART, Highly Active Anti-Retroviral Therapy.
a All selected patients had total adherence to the HAART.
L-6, IL-10, IL-12, IFN-2, TFN-, IP-10, MCP-1 and RANTES)
ere quantiﬁed using a multiplex assay (HCYTOMAG-60 K,
illiplex
®
kit, Merck Millipore, Germany) with Luminex
®
agpixTM technology (Austin, TX, USA). The assay was
erformed following the manufacturer’s instructions. The
ytokines/chemokines concentrations were calculated by Mil-
iplex Analyst 5.1
®
software using a standard curve with cubic
pline ﬁtting (log scale).
tatistical  analysis
ll data are presented as median with interquartile range
nd the classical statistical analysis was performed using
ruskal–Wallis test followed by Dunn’s test between all
olumns pairs. For correlation analysis was used Spear-
an’s two-tailed test and the networks of correlations of
ytokines/chemokines released was built using Cytoscape
oftware (v.3.2.0), classifying the interactions according to
he following ratio: negative (r < 0); weak (r < 0.36); moderate
0.36 < r < 0.67); or strong (r > 0.67). In both analyses, p ≤ 0.05
as considered signiﬁcant.
esults
IV-1  patients  under  regular  use  of  HAART  present  more
ronounced  impairment  of  cytokines/chemokines  released
rom  MDMs  after  PAMPs  stimuli
he present data show that classical MDMs derived from
oth treatment-naïve HIV-1 infected patients and HIV-
 + HAART groups expressed very similar levels of cytokines
nd chemokines after PAMPs stimuli. In spite of that, we
bserved an increase of IL-6 and IL-12 released by unstimu-
ated MDMs  derived from HIV-1 + HAART patients comparedPlease cite this article in press as: Galvão-Lima LJ, et al. Classical and altern
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
o control patients (Fig. S1). On the other hand, alternatively
ctivated MDMs  obtained from the analyzed groups showed a
ower level of IL-6, IL-10, TNF-, IP-10, and RANTES released by
IV-1 + HAART after LPS stimuli compared to control patients
Fig. S2).MDMs  obtained  from  treatment-naïve  HIV-1  infected
patients  present  several  impairments  in
cytokines/chemokines  expression  after  PAMPs  stimuli  and
these  alterations  were  not  restored  with  antiretroviral
therapy
To fully explore the impact of HAART on the development
of the MDM-dependent immune response, we  examined the
expression of cytokines/chemokines from classically or alter-
natively activated MDMs derived from treatment-naïve HIV-1
infected patients, HIV-1 + HAART or control groups after PAMP
stimuli.
At baseline (without PAMP stimuli), classical MDMs derived
from control patients expressed a few positive correlations,
especially strong between IL-1 ↔ IL-6 ↔ IL-10 (forming the
‘elementary triangle’) and moderate between IL-1 ↔ IL-10
and TNF- ↔ IL-12 ↔ IFN-2 ↔ MCP-1 (Fig. 1A). However, these
interactions changed when we  analyzed the MDM  cytokine
expression patterns obtained from treatment-naïve HIV-1
infected patients. In these patients the elementary triangle is
preserved, intensifying the correlation between IL-1 ↔ IL-10
and forming a new strong correlation amongst IL-12 ↔ IP-
10 ↔ IL-10 (Fig. 1B), suggesting a ‘primed’ proinﬂammatory
proﬁle of MDMs obtained from treatment-naïve HIV-1 infected
patients. In HIV-1 + HAART patients without PAMP stimuli,
the elementary triangle was similar to the control group,
with an increase of new moderate positive correlations
(IL-10 ↔ IL-12; TNF- ↔ RANTES) and, interestingly, a nega-
tive (IL-1 ↔ RANTES) correlation (Fig. 1C). Nevertheless, the
main changes observed amongst the groups with respect
to classical MDMs’ function occurred after PAMP stimuli.
The complex network observed after LPS stimuli on MDMs
derived from the control group (Fig. 1D) showed decreased
interactions among cytokines from treatment-naïve HIV-1
infected patients, particularly affecting IL-6, IL-12, TNF- and
IP-10 (Fig. 1E). Decreased cytokine correlations were strongly
accentuated in MDMs obtained from HIV-1 + HAART patients;ative macrophages have impaired function during acute and chronic
.10.004
in contrast, only six of 23 interactions obtained from the
control group were preserved (Fig. 1F). Similarly, after recog-
nition of -glucan, classical MDMs derived from the control
group formed a complex correlation network (Fig. 1G) that
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Fig. 1 – HIV-1 infection induces damage on cytokine and chemokine network formed by classical MDMs  that are not
restored even under HAART. The analysis of correlation between the cytokines and chemokines released by unstimulated,
LPS- or -glucan-stimulated classical MDMs was performed using Spearman’s two-tailed test. The network was built using
Cytoscape software (v3.2.0). Solid lines indicate strong correlations and dash-dot lines are representative of moderate
correlations. All the black lines represent positive correlations between the targets and the red lines are representative of
negative correlations.was progressively losing the ‘elementary triangle’ and other
important correlations seen in the treatment-naïve HIV-1
infected and HIV-1 + HAART groups–preserving only four inter-
actions vs 23 obtained in the control group (Fig. 1H and
I).
In parallel, the baseline analysis of alternative MDM  net-
work correlations revealed that the complex correlations
(including the elementary triangle) seen in the control group
was not present in treatment-naïve HIV-1 infected patients
(only seven of 20 previous interactions remained) and was only
partially restored in HIV-1 + HAART patients (with 10 of 20 cor-
relations observed), reducing the IL-10 and TNF- correlations
and increasing moderate interactions with IL-12 (Fig. 2A–C).
After stimuli with LPS and -glucan, a similar pattern of cor-
relation was observed amongst the groups, represented by
complex interactions in the control group (mainly based on
TNF-; Fig. 2D and G) and reduced numbers and intensity
of correlations found in MDMs  from treatment-naïve HIV-1
infected patients (Fig. 2E and H). Additionally, the analysis of
supernatants obtained from HIV-1 + HAART patients after LPS
and -glucan stimuli resulted in correlations similar to thosePlease cite this article in press as: Galvão-Lima LJ, et al. Classical and altern
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
found in the control group as well as two new negative corre-
lations among RANTES ↔ IL-1 ↔ IP-10 after -glucan stimuli
(Fig. 2F and I).Discussion
Classically, the term “macrophage” refers to a set of ter-
minally differentiated cells with low proliferation capacity
that have different names according to their localization.16
Despite the common name, macrophages do not represent
a homogeneous population and can originate from two  dis-
tinct embryological sources. The ﬁrst wave  of macrophages
is generated during early embryogenesis and is derived
from Yolk Sac progenitors, giving rise to physiological tis-
sue macrophages (named microglia, Langerhans cells, Kupffer
cells and alveolar macrophages) with the marked ability to
self-renew in the periphery.17–19 On the other hand, the sec-
ond wave of macrophages is derived from Hematopoietic
Stem Cells (HSCs) that become circulating blood monocytes,
which after migration to peripheral tissues differentiate into
MDMs.20
Under physiological conditions, MDMs display a full
spectrum of activation in different tissues, reﬂecting the
microenvironment milieu in which they ﬁnd themselves.21ative macrophages have impaired function during acute and chronic
.10.004
The recognition of PAMPs (e.g., LPS) and/or proinﬂammatory
cytokines induces the classical macrophage (M1) activation
pathway, related to Th1 CD4+ T cell activation, while the
ARTICLE IN PRESSBJID-666; No. of Pages 9
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Fig. 2 – HIV-1 infection induces damage on cytokine and chemokine networks formed by alternative MDMs  that are not
restored even under HAART. The analysis of correlation between the cytokines and chemokines released by unstimulated,
LPS- or -glucan-stimulated alternative MDMs  was performed using Spearman’s two-tailed test. The network was built
using Cytoscape software (v3.2.0). Solid lines indicate strong correlations and dash-dot lines are representative of moderate
correlations. All the black lines represent positive correlation between the targets and the red lines are representative of
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ecognition of glucocorticoids, immune complexes, or others
ytokines (e.g., IL-4, IL-10 and IL-13) induces the alternative
acrophage (M2) activation pathway, related to Th2 CD4+ T
ell activation.22,23
Although embryological distinct, both macrophage subsets
an productively be infected and contribute to HIV patho-
enesis during all stages of infection.24 The ﬁrst evidence of
IV-infected macrophages were published in the 1980s,25,26
ut it was not until recently this ﬁeld has been better explored.
n this context, our knowledge of macrophage function is
ased mainly on studies of MDMs  and new studies are crit-
cally needed to close the large gap of knowledge relating to
SDMs function during HIV infection (Fig. 3).
Over the years, different authors demonstrated that only
 few monocytes found on peripheral blood are infected by
IV-1,27,28 while others studies demonstrated that the virus
an directly infect bone marrow progenitors.29–31 Despite this
aradox, after migration to peripheral tissues, monocytes dif-
erentiate into macrophages and, even though expressing
everal factors restricting viral replication,32 these MDMs are
hronically infected and act as an important viral reservoir,
llowing HIV replication and spread to other cells (includingPlease cite this article in press as: Galvão-Lima LJ, et al. Classical and altern
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
D4+ T cells) during the normal time course of infection.11,33
his viral replication strategy is critical to HIV pathogenesis
nd gives these macrophages a ‘Trojan horse’ status, that canbe directly associated with the development of comorbidities,
such as immunosenescence and inﬂammatory/cardiovascular
diseases, and the progression to AIDS.34,35
Herein we  have shown the increase of IL-6 and IL-12
released from classical MDMs derived from HIV-1 + HAART.
This may be associated to prolonged time of infection and
higher baseline activation of macrophages induced by micro-
bial translocation from gut to systemic circulation, a common
phenomenon found in HIV infected patients.36 As conse-
quence of these events, a massive release of proinﬂammatory
cytokines (also known as ‘cytokine storm’) takes place in
plasma and the increase of baseline levels of cellular acti-
vation status. Interestingly, alternatively activated MDMs
obtained from HIV-1 + HAART patients release lower levels of
IL-6, IL-10, TNF-, IP-10, and RANTES compared to control
patients after LPS stimuli.
Based on these results, we hypothesized that the reduc-
tion of proinﬂammatory cytokines can be a secondary damage
induced by the chronicity of HIV infection and establish-
ment of viral reservoirs, which could be reprogramming the
macrophage function, or even could be induced by regu-
lar antiretroviral therapy. Despite the relevance of HAARTative macrophages have impaired function during acute and chronic
.10.004
in controlling viral load and restoring CD4+ T cells count
and CD4+/CD8+ T cell ratio in HIV infected patients, regular
HAART would impair macrophage function after PAMP stimuli
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Fig. 3 – Role of distinct macrophage populations on development of HIV-1 pathogenesis. Despite being ontogenically
distinct, YSDMs and MDMs  have a critical role in the maintenance of viral replication, reﬂected in the development of
chronic HIV-1 pathogenesis. MDMs  are derived from the terminal differentiation of myeloid bone marrow progenitor cells
and several studies have demonstrated that MDMs  obtained from HIV-1 patients have functional impairments in vitro.12–14
Although monocytes are poorly infected in the bloodstream, HIV-1 can infect directly CD34+ progenitor cells and induce
functional impairments during hematopoiesis.29–31 Some tissue macrophages are derived from monocyte differentiation of
peripheral tissues or from Yolk Sac progenitors seeded during the early steps of embryogenesis.17–19 Both of these subsets
can be chronically infected and cause the spread of virus to other cells. In parallel, microglia and other CNS (as perivascular
and meningeal) macrophages are directly derived from YS progenitors and contribute to development of neuronal death
and HAND found mainly on untreated HIV patients.24,33in these patients, which may be related to global reduction of
proinﬂammatory status found in HIV-infected patients. These
hypotheses are supported by the good therapeutic adherence
and the late infection stage on the onset of therapy of HIV-
1 + HAART patients (Table 1), suggesting that these failures
are due to prolonged time of HIV infection and also by the
treatment per se.
Taken together, our data reveal that alternatively activated
MDMs  are more  adversely affected after HIV-1 infection than
classically activated MDMs  and the antiretroviral therapy did
not completely restore the MDMs  functionality after PAMP
stimuli. These results are consistent with previous reports
demonstrating that alternatively activated macrophages are
more affected after contact with HIV-1 proteins. Further-Please cite this article in press as: Galvão-Lima LJ, et al. Classical and altern
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
more,  this contact induces the reprogramming of alternative
towards classical MDMs pattern, and this imbalance may be
associated with the spread of viral infection13 and the failureof T cell-dependent immune responses that further contribute
to development of AIDS.37
Undoubtedly, the development of antiretroviral drugs in
the 1990s and the improvement of therapeutic protocols have
changed the course of HIV-1 infection in the last 20 years.38,39
Currently, the FDA has approved 26 antiretrovirals for treating
HIV infection, including combined therapies that target dif-
ferent steps of viral entry or the replication cycle.40 Usually
after a few weeks on HAART, the viral load and the inﬂamma-
tory mediators decrease drastically in plasma, often falling to
undetectable levels and stabilizing the CD4+ T cells counts.
However, even under continuous therapy, patients maintain
HIV-1 replication in different tissue reservoirs that are respon-
sible for the long term persistence of viral infection.41 Basedative macrophages have impaired function during acute and chronic
.10.004
on the above positive results, the WHO  now recommends
antiretroviral therapies be made available to all patients diag-
nosed and living with HIV.42 Relatedly, our group and others
ARTICLE IN PRESSBJID-666; No. of Pages 9
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Fig. 4 – HIV-1 infection induces several impairments on classical and alternative MDMs  that were  not fully restored even
under regular HAART. After infection by HIV-1, MDMs  activation is inﬂuenced by interaction with viral proteins and
responsible for sustaining viral replication over different stages of infection. Classical and alternatively activated MDMs
present functional impairments – as reduction in phagocytic and intracellular killing activity and the general proﬁle of
cytokines/chemokine released after recognition of antigenic stimuli. Even under regular HAART, MDMs  obtained from
HIV-1+ patients are chronically infected and represent an important viral reservoir. The functional changes found in these
cells are only partially restored, impairing the development of appropriate immune responses against pathogens, allowing
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ecently have demonstrated that the adoption of HAART
orks to effectively reduce the viral load and the inﬂam-
ation biomarkers in plasma,43–45 reducing both the effects
f the systemic inﬂammatory disease and the comorbidi-
ies/mortality associated with HIV infection.46,47
Despite these therapeutic successes, no currently used
rug is able to restore the MDM  functional alterations induced
y HIV or directly strengthen the immune response of infected
atients. These ﬁndings indicate that we still need to develop
ew approaches and improve our current therapeutic proto-
ols, focusing on reestablishment of cellular functions and
revention/treatment of opportunistic infections.
Therefore, these observations suggest an important effect
f antiretroviral drugs on MDMs  function, even without
AMP stimuli in vitro. Under regular HAART, HIV-1+ patients
xhibited a pronounced reduction of inﬂammatory mediators
including sCD14, sCD163 and TF) associated with microbialPlease cite this article in press as: Galvão-Lima LJ, et al. Classical and altern
HIV-1 infection. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
ranslocation and development of comorbidities associated
ith infection,48–50 thus improving the life expectancy of these
atients. Recently, our group showed that treatment withsecond line therapy protocols do not restore the immune acti-
vation status, despite the reduction of viral load found in
plasma samples.43 In the present paper, we  examined MDMs
function during HIV-1 infection and demonstrated an impor-
tant reduction in cytokine/chemokine released by classically
and alternatively activated MDMs derived from HIV-1 infected
patients at baseline and after recognition of PAMP stimuli.
After all, it its unquestionable the relevance of HAART dur-
ing HIV infection and its beneﬁts to avoid AIDS development.
Several recent studies evidenced that the beginning of com-
bined antiretroviral therapy even in newly diagnosed patients
has a great epidemiological relevance and is being encour-
aged by WHO.51 Nonetheless, we cannot miss the point that
the current HAART protocols do not restore the impairments
found in macrophages or in other immune cells obtained
from HIV-infected patients, and these functional changes may
be associated to the development of other non-AIDS relatedative macrophages have impaired function during acute and chronic
.10.004
comorbidities (Fig. 4). In Brazil, since the year of 2014, all
HIV infected patients are entitled to start treatment irrespec-
tive of comorbidities or CD4+ T cell counting and viral load
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level.52 Therefore, in the data showed here, considering the
CD4+ T cell nadir, CD4+/CD8+ T cell ratio on diagnosis, and
the time elapsed since diagnosis and start of regular therapy,
the HIV-treated patients were in a late stage of infection com-
pared to the treatment-naïve HIV-1 infected group. In fact, the
advanced stages of HIV infection may induce several impair-
ments on immune response that could be reﬂected in our
cytokine data. Another point to consider is the immunosenes-
cence. It is well documented that HIV infection is related to
premature immunosenescence53,54 and the prolonged time of
infection could accelerate the occurrence of functional alter-
ations in macrophages. Thus, it is crucial that new adjuvant
therapies should be developed, considering the aim at restor-
ing cellular function while eliminating viral reservoirs.
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